Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | DNM2 | P50570 | 2/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691634 | 0.81 | TNNI3K (0.59) | SRCLRRK2EGFRTNNI3K | |
| SCHEMBL12431497 | 0.76 | THRB (0.57) | SRCLRRK2EGFRTNNI3KKDM4E | |
| SCHEMBL27408585 | 0.74 | EGFR (0.74) | EGFRDNM2TNNI3KMAPT | |
| SCHEMBL27408584 | 0.74 | EGFR (0.52) | EGFRDNM2TNNI3KKDM4EPOLB | |
| SCHEMBL2203654 | 0.74 | EGFR (0.47) | SRCLRRK2EGFRTNNI3KMAPK1 | |
| SCHEMBL14772971 | 0.74 | EGFR (0.45) | SRCLRRK2EGFRTNNI3KERBB3 | |
| SCHEMBL18177583 | 0.70 | EGFR (0.55) | SRCLRRK2EGFR | |
| SCHEMBL27337220 | 0.69 | EGFR (0.78) | EGFRTNNI3KMAPTMAPK1 | |
| SCHEMBL12262286 | 0.68 | ERBB2 (0.51) | SRCLRRK2EGFRAURKAERBB3 | |
| SCHEMBL8799214 | 0.68 | EGFR (0.83) | EGFRTNNI3KKDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SRC 526/4885LRRK2 1200/4885EGFR 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.